Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8971460 | 0.94 | PAOX (0.53) | ACHECYP1A2PAOXHDAC3HDAC4 | |
| SCHEMBL180477 | 0.92 | PAOX (0.57) | ACHECYP1A2PAOX | |
| SCHEMBL11572316 | 0.92 | PAOX (0.57) | ACHECYP1A2PAOX | |
| Trifluoroacetic Acid SCHEMBL594282 | 0.88 | ACHE (0.43) | ACHECYP1A2HDAC3HDAC4HDAC1 | |
| SCHEMBL21106400 | 0.87 | ACHE (0.50) | ACHECYP1A2 | |
| SCHEMBL6553610 | 0.87 | — | — | |
| SCHEMBL7570219 | 0.87 | ACHE (0.61) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL21068069 | 0.87 | ACHE (0.61) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1023071 | 0.85 | ACHE (0.61) | ACHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12417367 | 0.85 | ACHE (0.61) | ACHEHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230057718-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20200048638-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180066258-A1 | SPECIFIC SYNTHETIC CHIMERIC XENONUCLEIC ACID GUIDE RNA; s(XNA-gRNA) FOR ENHANCING CRISPR MEDIATED GENOME EDITING EFFICIENCY | POWELL MICHAEL J (US) | 2018-03-08 | — | — | US | disclosed |
| US-8389442-B2 | N-phenyl-′(4-pyridyl)-azinyl!amine derivatives as plant protection agents | SYNGENTA CROP PROTECTION LLC (US) | 2013-03-05 | — | — | US | disclosed |
| EP-1613156-B1 | N-PHENYL- \" (4-PYRIDYL)- AZINYL]AMINE DERIVATIVES AS PLANT PROTECTION AGENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-20070032490-A1 | N-Phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents | SYNGENTA CROP PROTECTION, INC. | 2007-02-08 | — | — | US | disclosed |
| US-7109197-B2 | N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1613156-A1 | N-PHENYL- \" (4-PYRIDYL)- AZINYL!AMINE DERIVATIVES AS PLANT PROTECTION AGENTS | Syngenta Participations AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| US-5298513-A | Serotonin antagonist | BAYER AKTIENGESELLSCHAFT (DE) | 1994-03-29 | — | — | US | disclosed |
| EP-0332968-B1 | 1,3,4,5-Tetrahydrobenz[c,d]indoles | BAYER AG (DE) | 1993-06-02 | — | — | EP | disclosed |
| EP-0270947-B1 | SUBSTITUTED BASIC 2-AMINOTETRALINES | BAYER AG (DE) | 1993-05-19 | — | — | EP | disclosed |
| US-5153225-A | For treating disorders of the central nervous system, cardiovascular system and intestinal tract | BAYER AKTIENGESELLSCHAFT (DE) | 1992-10-06 | — | — | US | disclosed |
| US-5137901-A | For binding 5-HT 1 receptors; treating central nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | disclosed |
| US-5026857-A | Cetnral nervous system disorders; antiserotonine agent | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-25 | — | — | US | disclosed |
| US-5021438-A | Having affinity for 5-hydroxytryptamine receptors; treating central nervous system and cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-04 | — | — | US | disclosed |
| EP-0352613-A2 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1990-01-31 | — | — | EP | disclosed |
| US-4880802-A | CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1989-11-14 | — | — | US | disclosed |
| US-4623690-A | Cathodically precipitable aqueous electro-dipcoating agent | HERBERTS GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1986-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032490-A1 | N-Phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents | CYP1A1, NAT1, AKR7A2 | ACHE 107/4885CYP1A2 4/4885PAOX 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.